RS61222B1 - Ciklopiroks, ciklopiroksolamin, ili prolek ciklopiroksa za upotrebu u lečenju kancera bešike - Google Patents
Ciklopiroks, ciklopiroksolamin, ili prolek ciklopiroksa za upotrebu u lečenju kancera bešikeInfo
- Publication number
- RS61222B1 RS61222B1 RS20201438A RSP20201438A RS61222B1 RS 61222 B1 RS61222 B1 RS 61222B1 RS 20201438 A RS20201438 A RS 20201438A RS P20201438 A RSP20201438 A RS P20201438A RS 61222 B1 RS61222 B1 RS 61222B1
- Authority
- RS
- Serbia
- Prior art keywords
- cpx
- ciclopirox
- pom
- bladder cancer
- prodrug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462078069P | 2014-11-11 | 2014-11-11 | |
| US201562134747P | 2015-03-18 | 2015-03-18 | |
| PCT/US2015/059955 WO2016077346A1 (en) | 2014-11-11 | 2015-11-10 | Methods of bladder cancer treatment with ciclopirox, ciclopirox olamine, or a ciclopirox prodrug |
| EP15859268.3A EP3217980B1 (en) | 2014-11-11 | 2015-11-10 | Ciclopirox, ciclopirox olamine, or a ciclopirox prodrug for use in the treatment of bladder cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS61222B1 true RS61222B1 (sr) | 2021-01-29 |
Family
ID=55954945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20201438A RS61222B1 (sr) | 2014-11-11 | 2015-11-10 | Ciklopiroks, ciklopiroksolamin, ili prolek ciklopiroksa za upotrebu u lečenju kancera bešike |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20170304329A1 (https=) |
| EP (1) | EP3217980B1 (https=) |
| JP (1) | JP2017533952A (https=) |
| CN (2) | CN116687941A (https=) |
| DK (1) | DK3217980T3 (https=) |
| ES (1) | ES2836208T3 (https=) |
| HR (1) | HRP20201893T1 (https=) |
| HU (1) | HUE052670T2 (https=) |
| PT (1) | PT3217980T (https=) |
| RS (1) | RS61222B1 (https=) |
| WO (1) | WO2016077346A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112351970A (zh) * | 2018-05-30 | 2021-02-09 | 科莱恩国际有限公司 | 2-羟基吡啶-1-氧化物或其衍生物的形成方法 |
| CN113194945B (zh) * | 2018-08-23 | 2024-07-23 | 佩勒梅德有限公司 | 环吡酮的抑制hbv核心组装的用途 |
| WO2021078937A1 (en) * | 2019-10-25 | 2021-04-29 | Deutsches Krebsforschungszentrum | Treatment of stat3 related diseases by iron chelators |
| EP4193989A1 (en) | 2021-12-09 | 2023-06-14 | Atlas Molecular Pharma, S.L. | A formulation for an effective oral administration of ciclopirox with no adversal gasterointestinal toxicity |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU754965B2 (en) | 1997-12-31 | 2002-11-28 | University Of Kansas, The | Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof |
| AU2003251875A1 (en) * | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Combination therapy for the treatment of neoplasms |
| US20110212176A1 (en) | 2008-10-31 | 2011-09-01 | University Health Network | Ciclopirox and cytarabine for the treatment of leukemic disorders |
| EP2576513A1 (en) * | 2010-06-01 | 2013-04-10 | Biotheryx Inc. | Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases |
| JP5853028B2 (ja) * | 2010-12-02 | 2016-02-09 | カンザス大学 | ６−シクロヘキシル−１−ヒドロキシ−４−メチルピリジン−２（１ｈ）−オンのプロドラッグおよびその誘導体 |
-
2015
- 2015-11-10 CN CN202310102470.8A patent/CN116687941A/zh active Pending
- 2015-11-10 HU HUE15859268A patent/HUE052670T2/hu unknown
- 2015-11-10 RS RS20201438A patent/RS61222B1/sr unknown
- 2015-11-10 JP JP2017526594A patent/JP2017533952A/ja active Pending
- 2015-11-10 DK DK15859268.3T patent/DK3217980T3/da active
- 2015-11-10 ES ES15859268T patent/ES2836208T3/es active Active
- 2015-11-10 HR HRP20201893TT patent/HRP20201893T1/hr unknown
- 2015-11-10 PT PT158592683T patent/PT3217980T/pt unknown
- 2015-11-10 CN CN201580061284.8A patent/CN107206012A/zh active Pending
- 2015-11-10 US US15/526,164 patent/US20170304329A1/en not_active Abandoned
- 2015-11-10 WO PCT/US2015/059955 patent/WO2016077346A1/en not_active Ceased
- 2015-11-10 EP EP15859268.3A patent/EP3217980B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016077346A1 (en) | 2016-05-19 |
| HUE052670T2 (hu) | 2021-05-28 |
| EP3217980A4 (en) | 2018-05-02 |
| CN107206012A (zh) | 2017-09-26 |
| US20170304329A1 (en) | 2017-10-26 |
| PT3217980T (pt) | 2020-12-11 |
| CN116687941A (zh) | 2023-09-05 |
| JP2017533952A (ja) | 2017-11-16 |
| ES2836208T3 (es) | 2021-06-24 |
| DK3217980T3 (da) | 2020-12-07 |
| EP3217980B1 (en) | 2020-10-14 |
| HRP20201893T1 (hr) | 2021-02-05 |
| EP3217980A1 (en) | 2017-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10822339B2 (en) | Pyrrolopyrimidine five-membered azacyclic derivative and application thereof | |
| US10450305B2 (en) | LKB1-AMPK activators for therapeutic use in polycystic kidney disease | |
| US9545413B2 (en) | Methods of forming ciclopirox or derivatives thereof in a subject by administration of prodrug | |
| EP1663219B1 (fr) | Derives d'indole pour le traitement de maladies liees au processus d'epissage | |
| RS61222B1 (sr) | Ciklopiroks, ciklopiroksolamin, ili prolek ciklopiroksa za upotrebu u lečenju kancera bešike | |
| US12595227B2 (en) | Compositions and methods for treatment of platinum-based chemotherapeutic resistant tumors | |
| Prakash et al. | Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl) 1 H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis | |
| KR101990214B1 (ko) | 표적 특이적 항암 약물전구체 | |
| EP3113767B1 (en) | Mtor-independent activator of tfeb for autophagy enhancement and uses thereof | |
| CN120943822A (zh) | 激酶抑制剂 | |
| US9012455B2 (en) | Pharmaceutical compositions containing an indoyl isoquinoline containing compound and uses thereof | |
| TWI415613B (zh) | Anti-cancer agent resistance to overcome the agent | |
| US10494365B2 (en) | Small molecule inhibitor of 3-phosphoglycerate dehydrogenase and uses thereof | |
| EP3549930A1 (en) | Novel ester compound and pin1 inhibitor, inflammatory disease therapeutic, and colon cancer therapeutic in which said ester compound is used | |
| US9540299B2 (en) | MTOR-independent activator of TFEB for autophagy enhancement and uses thereof | |
| US9399644B2 (en) | [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer | |
| Wang et al. | Discovery of a Novel EGFR PROTAC Degrader against C797S Resistance Mutation with Potent Antitumor Efficacy in NSCLC Treatment | |
| EP3558304A2 (en) | Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases | |
| CN102532192A (zh) | 一种对乙酰氨基酚—磷酰氮芥抗肿瘤药物及其制备方法 | |
| US20230322853A1 (en) | Compounds and compositions for the treatment of proliferative diseases and disorders | |
| CN110882395B (zh) | 一种ros响应性jak3共价抑制剂前药、制备方法及治疗类风湿性关节炎的用途 | |
| Ju et al. | Exploration of new azole derivatives containing ethanolamine moiety as anti-UC agents by inhibiting NF-κB/MAPK pathways | |
| WO2025194120A1 (en) | Zwitterionic polymer functionalized lipid nanoparticles for delivery of nucleic acids | |
| US20090131511A1 (en) | Palmarumycin based inhibitors of thioredoxin and methods of using same | |
| CN119977961A (zh) | 一种protac化合物及其制备方法和作为靶向tau的降解剂的应用 |